HR 4200
110th Congress
House
Taxation
Antibiotics
Commerce
Communicable diseases
Drug industry
Health
Income tax
Medical tests
Pharmaceutical research
Preventive medicine
Research and development tax credit
Science, Technology, Communications
Vaccines
Virus diseases
To amend the Internal Revenue Code of 1986 to provide a tax credit for medical research related to developing qualified infectious disease products.
Introduced: November 15, 2007
See on congress.gov
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 15, 2007
Referred to the House Committee on Ways and Means.
Nov 15, 2007
Introduced in House
Plain-English summary
Amends the Internal Revenue Code to allow a general business tax credit for 50% of expenses paid for research and development of any qualified infectious disease product. Defines "qualified infectious disease product" as any antibiotic drug, antiviral, diagnostic test, biological product, or vaccine developed to treat, detect, prevent, or identify certain pathogens. Terminates such credit after 2012.
What's happening now
Referred to the House Committee on Ways and Means.
Committees of jurisdiction
1
Cosponsors
1